Sgltr V Tablet 10

The SGLTR-V Tablet is used:

• To enhance glycemic control in cases where metformin and one of the individual components of the fixed-dose combination of remogliflozin etabonate & vildagliptin are insufficient
• When currently undergoing treatment with individual combination of remogliflozin etabonate & vildagliptin

• Swallow the entire tablet without crushing or breaking it. 
• Take it with or without food, but it is recommended at a fixed daily time for better results.

The SGLTR-V Tablet is taken orally.

SGLTR-V Tablet contains the following components:

• Remogliflozin Etabonate (100 mg): Remogliflozin etabonate serves as the precursor to remogliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2). This mechanism facilitates urinary glucose excretion, contributing to the alleviation of hyperglycemia in treating type 2 diabetes.
• Vildagliptin (50 mg): It is a DPP-4 inhibitor which promptly and entirely inhibits DPP-4 activity. This inhibition leads to elevated fasting and postprandial levels of endogenous incretin hormones, including GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

• The SGLTR-V Tablet should be stored at room temperature, at 25°C.
• Please protect it from light and moisture.
• Keep away from children.
• Do not use this medicine after the expiry date has passed.

• Incorporate foods abundant in healthy carbohydrates and fiber, including fruits, whole grains, and vegetables, into your diet.
• Adopt a regular eating schedule, avoiding meal skips and overeating.
• Adhere to a nutritious diet and take a 45-minute walk to complement the SGLTR-V Tablet treatment.
• Sustain a healthy weight through regular exercise.
• Ensure proper rest, and mitigate stress through meditation or yoga.